CatalystMarker
Sign in
← board

SNY

Sanofidistress 1/10 · well-funded / low risk
$43.08-2%today-18% from 52w high
sanofi.com74,846 employeesFounded 1994Paris, FranceDrug Manufacturers - General
Immunology / Inflammation 1
Lead: Crohn's Disease · est. market ~$12B (approx, global)
Revenue
$11244M
Liquidity
$12155M
Runway
—
Shares 1y
0%

Price & events

-2.2% over 6M
$41.31$43.98$46.66Jan 26Apr 26Jul 2610.9M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-2.6%
1W
+3.5%
1M
-4.3%
3M
-3.7%
6M
-9.4%
1Y
-5.9%
2Y
+2.9%
5Y
+13.6%
All

Overview

Market Cap
$52.53B
Enterprise Value
$59.28B
Volume
184.71K
52 Week Range
$41.33 – $52.34
Total Shares
1.22B
Float Shares
2.18B
Short %
0.31%
% Held by Insiders
0.00%
% Held by Institutions
8.88%
RVOL
0.05x
Beta
0.28

Pipeline stages · 40 programs

Isatuximab SAR650984, Lenalidomide, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-11-30
Rilzabrutinib, Glucocorticoid
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-11-30
Itepekimab (SAR440340)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-01
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-01
Pandemic flu H5 HA mRNA SD2 vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-01
SAR442970
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-17
Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-23
efanesoctocog alfa (BIVV001)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-15
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigation
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-18
SAR445877, Cetuximab, ADG126
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-19
Show all 40 programs · 30 more ▾
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin conc
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-03-25
SAR444336
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-08
Brivekimig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-29
Riliprubart Prefilled Pen (PFP)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-17
Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-17
SAR402663, Diluent
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-18
Dupilumab, Fexofenadine (loratadine if not available)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-02
Lunsekimig, Short-Acting Beta Agonists (SABA), Fluticasone/Salmeterol
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-21
SAR441566
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-21
SAR445399
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09-22
Amlitelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09-30
SAR446597, Sham Comparator
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-13
Dupilumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-28
Chlamydia mRNA Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-03
SAR448501
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-21
Sarilumab SAR153191 (REGN88)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03-01
Teplizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03-06
Duvakitug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-05-09
SAR447537
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-30
Belumosudil, Azithromycin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-25
Acne mRNA vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-30
SAR446268
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-28
Tolebrutinib, Teriflunomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04-30
Lunsekimig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-11-27
SAR444836
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-04-02
balinatunfib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-05-10
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-01-29
SAR446523
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-05-16
Blood draw for the laboratory assessment
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-06-13
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2033-08-29

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-11-30
Estimated 50%
readout ~2027-01-14
Phase 2Isatuximab intravenous (IV), Cemiplimab (SAR439684), DexamethasonePlasma Cell Myeloma—active not recruiting
2026-11-30
Estimated 50%
readout ~2027-02-13
Phase 3rilzabrutinibImmune Thrombocytopenia—active not recruiting
2026-12-01
Estimated 50%
readout ~2027-02-14
Phase 3PCV21, 20vPCVPneumococcal Infections—active not recruiting
2026-12-01
Estimated 50%
readout ~2027-02-14
Phase 3Itepekimab (SAR440340)Chronic Obstructive Pulmonary Disease—active not recruiting
2026-12-01
Estimated 50%
readout ~2027-01-15
Phase 1/2Pandemic flu H5 HA mRNA SD2 vaccinePandemic Influenza Immunization, Healthy Volunteers—active not recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2026-12-17
Estimated 50%
readout ~2027-01-31
Phase 2SAR442970Ulcerative Colitis—recruiting
2026-12-17
Estimated 50%
readout ~2027-01-31
Phase 2SAR442970Crohn's Disease—recruiting
2026-12-23
Estimated 50%
readout ~2027-02-06
Phase 2frexalimab, brivekimig, rilzabrutinibFocal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion—recruiting
2027-01-07
Estimated 50%
readout ~2027-03-23
Phase 3PCV21, 20vPCVSickle Cell Disease—recruiting
2027-01-08
Estimated 50%
readout ~2027-02-22
Phase 2Isatuximab SC-OBDS, Montelukast, DexamethasonePlasma Cell Myeloma Refractory—recruiting
2027-01-15
Estimated 50%
readout ~2027-03-31
Phase 3efanesoctocog alfa (BIVV001)Hemophilia A—active not recruiting
2027-01-18
Estimated 50%
readout ~2027-03-04
Phase 1/2Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), InvestigationHuman Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization—active not recruiting
2027-01-19
Estimated 50%
readout ~2027-03-05
Phase 1/2SAR445877, Cetuximab, ADG126Solid Tumor—recruiting
2027-03-25
Estimated 50%
readout ~2027-06-08
Phase 3Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concHemophilia—active not recruiting
2027-04-05
Estimated 50%
readout ~2027-06-19
Phase 3Isatuximab SAR650984, Bortezomib, LenalidomidePlasma Cell Myeloma—active not recruiting
2027-04-08
Estimated 50%
readout ~2027-05-23
Phase 2SAR444336Microscopic Colitis—recruiting
2027-04-28
Estimated 50%
readout ~2027-06-12
Phase 2Frexalimab, InsulinType 1 Diabetes Mellitus—active not recruiting
2027-04-29
Estimated 50%
readout ~2027-06-13
Phase 2BrivekimigType 1 Diabetes Mellitus—active not recruiting
2027-05-06
Estimated 50%
readout ~2027-07-20
Phase 3Frexalimab, Teriflunomide, MRI contrast-enhancing agentsMultiple Sclerosis—active not recruiting
2027-05-17
Estimated 50%
readout ~2027-07-31
Phase 3RiliprubartChronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic—recruiting
2027-05-17
Estimated 50%
readout ~2027-07-01
Phase 1/2Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B Meningococcal Immunization, Healthy Volunteers—active not recruiting
2027-05-17
Estimated 50%
readout ~2027-07-31
Phase 3PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccinePneumococcal Immunization—active not recruiting
2027-05-18
Estimated 50%
readout ~2027-07-02
Phase 1/2SAR402663, DiluentNeovascular Age-related Macular Degeneration—recruiting
2027-06-02
Estimated 50%
readout ~2027-08-16
Phase 3Dupilumab, Fexofenadine (loratadine if not available)Pruritus—recruiting
2027-06-07
Estimated 50%
readout ~2027-08-21
Phase 3PCV21 vaccine, 20vPCV licensed vaccinePneumococcal Immunization, Healthy Volunteers—recruiting
2027-06-21
Estimated 50%
readout ~2027-08-05
Phase 2Lunsekimig, Short-Acting Beta Agonists (SABA), Fluticasone/SalmeterolAsthma—active not recruiting
2027-07-09
Estimated 50%
readout ~2027-09-22
Phase 3riliprubart, IVIgChronic Inflammatory Demyelinating Polyneuropathy—recruiting
2027-07-15
Estimated 50%
readout ~2027-09-28
Phase 3Frexalimab, MRI contrast-enhancing preparationsMultiple Sclerosis—recruiting
2027-07-21
Estimated 50%
readout ~2027-09-04
Phase 2SAR441566Crohn's Disease—recruiting
2027-07-23
Estimated 50%
readout ~2027-10-06
Phase 3RilzabrutinibSickle Cell Disease—recruiting
2027-07-29
Estimated 50%
readout ~2027-09-12
Phase 2SAR441566Colitis Ulcerative—recruiting
2027-08-01
Estimated 50%
readout ~2027-09-15
Phase 2BrivekimigHidradenitis Suppurativa—recruiting
2027-08-25
Estimated 50%
readout ~2027-11-08
Phase 3PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccinePneumococcal Immunization, Healthy Volunteers—active not recruiting
2027-09-10
Estimated 50%
readout ~2027-11-24
Phase 3PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccinePneumococcal Immunization—active not recruiting
2027-09-13
Estimated 50%
readout ~2027-10-28
Phase 1/2Isatuximab, Dexamethasone, PomalidomidePlasma Cell Myeloma Refractory—recruiting
2027-09-22
Estimated 50%
readout ~2027-11-06
Phase 2SAR445399Hidradenitis Suppurativa—recruiting
2027-09-30
Estimated 50%
readout ~2027-12-14
Phase 3Amlitelimab, Topical corticosteroids, Topical tacrolimus or pimecrolimusDermatitis Atopic—recruiting
2027-10-13
Estimated 50%
readout ~2027-11-27
Phase 1/2SAR446597, Sham ComparatorGeographic Atrophy—recruiting
2027-10-20
Estimated 50%
readout ~2028-01-03
Phase 3Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal Polyps—not yet recruiting
2027-10-22
Estimated 50%
readout ~2028-01-05
Phase 3PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccinePneumococcal Immunization—active not recruiting
2027-10-28
Estimated 50%
readout ~2028-01-11
Phase 3DupilumabPrurigo Nodularis—recruiting
2027-10-29
Estimated 50%
readout ~2027-12-13
Phase 2SAR445399Non-cystic Fibrosis Bronchiectasis—recruiting
2027-11-05
Estimated 50%
readout ~2028-01-19
Phase 3rilzabrutinibImmune Thrombocytopenia—recruiting
2028-01-03
Estimated 50%
readout ~2028-02-17
Phase 1/2Chlamydia mRNA VaccineChlamydia Trachomatis Immunization—recruiting
2028-01-21
Estimated 50%
readout ~2028-02-20
Phase 1SAR448501B-cell Non Hodgkin Lymphoma—recruiting
2028-03-01
Estimated 50%
readout ~2028-04-15
Phase 2Sarilumab SAR153191 (REGN88)Juvenile Idiopathic Arthritis—recruiting
2028-03-06
Estimated 50%
readout ~2028-04-20
Phase 2TeplizumabType 1 Diabetes Mellitus—recruiting
2028-03-24
Estimated 50%
readout ~2028-06-07
Phase 3Frexalimab, MRI contrast-enhancing agentsMultiple Sclerosis—active not recruiting
2028-05-09
Estimated 50%
readout ~2028-07-23
Phase 3DuvakitugUlcerative Colitis—recruiting
2028-05-31
Estimated 50%
readout ~2028-08-14
Phase 3rilzabrutinibAutoimmune Haemolytic Anaemia—recruiting
2028-06-06
Estimated 50%
readout ~2028-08-20
Phase 3TeplizumabType 1 Diabetes Mellitus—recruiting
2028-06-28
Estimated 50%
readout ~2028-09-11
Phase 3Rilzabrutinib, GlucocorticoidImmunoglobulin G4 Related Disease—recruiting
2028-06-30
Estimated 50%
readout ~2028-08-14
Phase 2SAR447537Alpha 1-Antitrypsin Deficiency, Emphysema—active not recruiting
2028-09-21
Estimated 50%
readout ~2028-12-05
Phase 3DuvakitugUlcerative Colitis—recruiting
2028-09-25
Estimated 50%
readout ~2028-11-09
Phase 2BelumosudilChronic Graft Versus Host Disease—recruiting
2028-09-29
Estimated 50%
readout ~2028-12-13
Phase 3Belumosudil, Prednisone, PrednisoloneChronic Graft Versus Host Disease—active not recruiting
2028-11-30
Estimated 50%
readout ~2029-01-14
Phase 1/2Acne mRNA vaccineAcne—recruiting
2028-12-12
Estimated 50%
readout ~2029-02-25
Phase 3Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal Polyps—enrolling by invitation
2028-12-21
Estimated 50%
readout ~2029-03-06
Phase 3DupilumabWheezing, Asthma—recruiting
2029-01-22
Estimated 50%
readout ~2029-04-07
Phase 2/3Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitorsDermatitis Atopic—enrolling by invitation
2029-01-29
Estimated 50%
readout ~2029-04-14
Phase 3Belumosudil, AzithromycinLung Transplant Rejection—recruiting
2029-02-28
Estimated 50%
readout ~2029-04-14
Phase 1/2SAR446268Myotonic Dystrophy—recruiting
2029-04-30
Estimated 50%
readout ~2029-07-14
Phase 3Tolebrutinib, TeriflunomideRelapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis—active not recruiting
2029-05-14
Estimated 50%
readout ~2029-07-28
Phase 3DuvakitugCrohn's Disease—recruiting
2029-06-19
Estimated 50%
readout ~2029-08-03
Phase 1/2Acne mRNA vaccineAcne—recruiting
2029-08-04
Estimated 50%
readout ~2029-10-18
Phase 3Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concHemophilia—recruiting
2029-08-13
Estimated 50%
readout ~2029-10-27
Phase 3DuvakitugCrohn's Disease—recruiting
2029-08-15
Estimated 50%
readout ~2029-10-29
Phase 2/3Frexalimab, Tacrolimus, rabbit anti-thymocyte globulinKidney Transplant Rejection—recruiting
2029-10-03
Estimated 50%
readout ~2029-12-17
Phase 3Riliprubart Prefilled Pen (PFP)Polyneuropathy, Inflammatory Demyelinating, Chronic—enrolling by invitation
2029-11-27
Estimated 50%
readout ~2030-02-10
Phase 3LunsekimigChronic Obstructive Pulmonary Disease—recruiting
2029-11-27
Estimated 50%
readout ~2030-02-10
Phase 3LunsekimigChronic Obstructive Pulmonary Disease—recruiting
2030-04-02
Estimated 50%
readout ~2030-05-17
Phase 1/2SAR444836Phenylketonuria—active not recruiting
2030-05-10
Estimated 50%
readout ~2030-06-24
Phase 2balinatunfibColitis Ulcerative, Crohn's Disease—enrolling by invitation
2030-10-14
Estimated 50%
readout ~2030-12-28
Phase 3Isatuximab SAR650984, Lenalidomide, DexamethasonePlasma Cell Myeloma—active not recruiting
2031-01-20
Estimated 50%
readout ~2031-03-06
Phase 2LunsekimigAsthma—enrolling by invitation
2031-01-29
Estimated 50%
readout ~2031-03-15
Phase 2Lunsekimig, Mometasone furoate nasal spray (MFNS)Chronic Rhinosinusitis With Nasal Polyps—enrolling by invitation
2031-05-16
Estimated 50%
readout ~2031-06-15
Phase 1SAR446523Plasma Cell Myeloma Refractory—recruiting
2031-06-11
Estimated 50%
readout ~2031-07-26
Phase 2AmlitelimabDermatitis Atopic—active not recruiting
2031-06-13
Estimated 50%
readout ~2031-07-28
Phase 2Blood draw for the laboratory assessmentUsher's Syndrome—active not recruiting
2033-08-29
Estimated 50%
readout ~2033-10-13
Phase 2Long term follow up in all patients who received SAR422459 in previous study TDU13583Stargardt's Disease—active not recruiting

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (14)

  • WAYRILZRILZABRUTINIB2025 · Prescription
  • QFITLIAFITUSIRAN SODIUM2025 · Prescription
  • XENPOZYMEOLIPUDASE ALFA-RPCP2022 · Prescription
  • NEXVIAZYMEAVALGLUCOSIDASE ALFA-NGPT2021 · Prescription
  • CERDELGAELIGLUSTAT TARTRATE2014 · Prescription
  • CAPRELSAVANDETANIB2011 · Prescription
  • LUMIZYMEALGLUCOSIDASE ALFA2010 · Prescription
  • RENVELASEVELAMER CARBONATE2009 · Prescription
  • MOZOBILPLERIXAFOR2008 · Prescription
  • MYOZYMEALGLUCOSIDASE ALFA2006 · Prescription

Capital structure — dilution & financing

Shares out: 1,219,427,096 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $55 (+28% upside) · 9 analysts
  • 2026-01-16UBSBuy → Neutral
  • 2026-01-06BarclaysOverweight → Equal-Weight
  • 2025-12-09GuggenheimBuy → Neutral
  • 2025-12-08JP MorganOverweight → Neutral
  • 2025-09-08Morgan StanleyEqual-Weight → Overweight
  • 2025-09-02Deutsche BankHold → Buy

Competitors — Crohn's Disease

  • LLYELI LILLY & Co$1094.4B · D3
  • JNJJOHNSON & JOHNSON$617.4B · D0
  • ABBVAbbVie Inc.$451.1B · D2
  • MRKMerck & Co., Inc.$318.8B · D3
  • TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
  • STTKShattuck Labs, Inc.$523M · D6
  • PALIPALISADE BIO, INC.$372M · D5
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.